Treatment of von Willebrand's Disease.
Angelo Bianchi Bonomi Hemophilia and Thrombosis Center and the Department of Internal Medicine and Dermatology, Istituto di Ricovero e Cura a Carattere Scientifico Maggiore Hospital and the University of Milan, Milan. piermannuccio.mannucci@unimi.it
Pier Mannuccio
PM
Mannucci
D000614:Aminocaproates / Q000627:therapeutic use; D016913:Blood Component Transfusion; D003894:Deamino Arginine Vasopressin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D005169:Factor VIII / Q000737:chemistry / Q000502:physiology / Q000627:therapeutic use; D005260:Female; D006467:Hemophilia A / Q000503:physiopathology / Q000628:therapy; D006487:Hemostasis / Q000502:physiology; D006801:Humans; D007518:Isoantibodies; D008595:Menorrhagia / Q000209:etiology; D010641:Phenotype; D010949:Plasma; D011247:Pregnancy; D011250:Pregnancy Complications, Hematologic / Q000188:drug therapy; D014148:Tranexamic Acid / Q000627:therapeutic use; D014842:von Willebrand Diseases / Q000145:classification / Q000175:diagnosis / Q000503:physiopathology / Q000628:therapy*; D014841:von Willebrand Factor / Q000737:chemistry / Q000502:physiology* / Q000627:therapeutic use
D000614:Aminocaproates; D007518:Isoantibodies; D014841:von Willebrand Factor; D014148:Tranexamic Acid; D005169:Factor VIII; D003894:Deamino Arginine Vasopressin